MarketPeel
Insider Trading Intelligence
EO

Erik Ostrowski

AKBA
SVP, CFO, CBO & TREASURER · AKEBIA THERAPEUTICS, INC. · CIK 0001762507
FILING MIX · LIFETIME67%/33%
BUYS
6
SELLS
3
TOTAL VALUE
$262.4K
COMPANIES
1
ACTIVE SINCE
Jun 2024
HOLDINGS NOW
616,616
AVG SELL PX
$1.98
TRADE KIND
SHOWING 9 / 9
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
2 backtested trades · 8 horizons · 4 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Erik Ostrowski, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d2+50.00%+4.21%+0.12%+4.09%+4.09%
14d2+50.00%-1.99%-0.34%-1.65%-1.65%
30d2+50.00%-4.43%+0.60%-5.04%-5.04%
60d2+50.00%-6.87%-0.65%-6.22%-6.22%
90d2+50.00%-8.43%+5.33%-13.76%-13.76%
180d2(1 pending)+100.00%-54.40%+11.73%-66.12%-66.12%
1y2(1 pending)+100.00%-68.54%+19.93%-88.48%-88.48%
2y2(2 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
AKBA · 616,616 shares · as of Jun 29, 2026
0176,897353,793530,690707,58620252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 6 buys / 3 sellsCOVERAGE · 9 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
AKBA
AKEBIA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
56,019$1.11$62.2K616,616Jun 29, 2026Jul 1, 2026View →
AKBA
AKEBIA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
34,951$1.39$48.6K672,635Feb 2, 2026Feb 4, 2026View →
AKBA
AKEBIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
204,000707,586Jan 30, 2026Feb 3, 2026View →
AKBA
AKEBIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
320,000320,000Jan 30, 2026Feb 3, 2026View →
AKBA
AKEBIA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
41,314$3.67$151.6K503,586Jun 30, 2025Jul 1, 2025View →
AKBA
AKEBIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
292,300292,300Jan 31, 2025Feb 4, 2025View →
AKBA
AKEBIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
194,900544,900Jan 31, 2025Feb 4, 2025View →
AKBA
AKEBIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
500,000500,000Jun 28, 2024Jul 2, 2024View →
AKBA
AKEBIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
350,000350,000Jun 28, 2024Jul 2, 2024View →
Other insiders · AKBA
Loading peer insiders…
About this filer
CIK 0001762507
ROLE
SVP, CFO, CBO & Treasurer
PRIMARY
AKBA
COMPANIES
1
ACTIVE SINCE
Jun 2024
MARKETPEEL · /INSIDER/0001762507DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback